ML-CDN2 was used to predict the response of all TCGA BC samples to lapatinib, a HER2/EGFR tyrosine kinase inhibitor used to treat HER2 positive BC, and tamoxifen, a SERM used to treat ER positive BC. Here, ERBB2 is linked to breast cancer.